Skip to main content

Advertisement

SpringerLink
Log in

Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Small cell carcinoma of the bladder (SCCB) is a rare disease associated with high invasiveness and mortality. Histologically, SCCB is difficult to distinguish from small cell lung cancer (SCLC); however, it shares more similar molecular alterations with urothelial carcinoma (UC). As a result, now, the widely accepted theory about the cells of origin is that SCCB and UC probably have a common clone origin. Even the former probably comes from a preexisting UC. At present, given its rarity, early diagnoses, treatments, and follow-ups are not well established, which are vital to patients with SCCB. Inspirationally, in recent years, with the development of molecular diagnostic methods, molecular alterations of SCCB have been understood partially, which are propitious to excavate new potential therapeutic strategies and establish sound follow-ups. Therefore, the future will be light for patients with SCCB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442.

    Article  PubMed  Google Scholar 

  2. Niu Q, Lu Y, Xu S, Shi Q, Guo B, Guo Z, et al. Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study. Cancer Manag Res. 2018;10:4479–89. https://doi.org/10.2147/CMAR.S175286.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol. 2016;70(1):106–19. https://doi.org/10.1016/j.eururo.2016.02.028.

    Article  PubMed  Google Scholar 

  4. Erdem GU, Ozdemir NY, Demirci NS, Sahin S, Bozkaya Y, Zengin N. Small cell carcinoma of the urinary bladder: changing trends in the current literature. Curr Med Res Opin. 2016;32(6):1013–21. https://doi.org/10.1185/03007995.2016.1155982.

    Article  PubMed  Google Scholar 

  5. Schreiber D, Rineer J, Weiss J, Leaf A, Karanikolas N, Rotman M, et al. Characterization and outcomes of small cell carcinoma of the bladder using the surveillance, epidemiology, and end results database. Am J Clin Oncol Cancer. 2013;36(2):126–31. https://doi.org/10.1097/COC.0b013e3182438c71.

    Article  Google Scholar 

  6. Chang MT, Penson A, Desai NB, Socci ND, Shen R, Seshan VE, et al. Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clin Cancer Res. 2018;24(8):1965–73. https://doi.org/10.1158/1078-0432.CCR-17-2655.

    Article  CAS  PubMed  Google Scholar 

  7. Shen PY, Jing Y, Zhang RY, Cai MC, Ma P, Chen H, et al. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics. Oncogene. 2018;37(22):3039–44. https://doi.org/10.1038/s41388-018-0192-5.

    Article  CAS  PubMed  Google Scholar 

  8. Oser MG, Janne PA. Small-cell neuroendocrine tumors: cell state trumps the oncogenic driver. Clin Cancer Res. 2018;24(8):1775–6. https://doi.org/10.1158/1078-0432.CCR-17-3646.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540.e25–556.e25. https://doi.org/10.1016/j.cell.2017.09.007.

    Article  CAS  Google Scholar 

  10. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44(10):1104–10. https://doi.org/10.1038/ng.2396.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Augert A, Zhang Q, Bates B, Cui M, Wang X, Wildey G, et al. Small cell lung cancer exhibits frequent inactivating mutations in the histone methyltransferase KMT2D/MLL2: CALGB 151111 (alliance). J Thorac Oncol. 2017;12(4):704–13. https://doi.org/10.1016/j.jtho.2016.12.011.

    Article  PubMed  Google Scholar 

  12. Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36(28):3943–56. https://doi.org/10.1038/onc.2016.502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268–86. https://doi.org/10.1101/gad.190678.112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495–501. https://doi.org/10.1038/nature12912.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Berman-Booty LD, Knudsen KE. Models of neuroendocrine prostate cancer. Endocr Relat Cancer. 2015;22(1):R33–49. https://doi.org/10.1530/ERC-14-0393.

    Article  CAS  PubMed  Google Scholar 

  16. Di Agostino S, Fontemaggi G, Strano S, Blandino G, D’Orazi G. Targeting mutant p53 in cancer: the latest insights. J Exp Clin Cancer Res. 2019;38(1):290. https://doi.org/10.1186/s13046-019-1302-0.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26(2):199–212. https://doi.org/10.1038/s41418-018-0246-9.

    Article  PubMed  Google Scholar 

  18. Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death Differ. 2018;25(1):161–8. https://doi.org/10.1038/cdd.2017.185.

    Article  CAS  PubMed  Google Scholar 

  19. Nag S, Zhang X, Srivenugopal KS, Wang MH, Wang W, Zhang R. Targeting MDM2-p53 interaction for cancer therapy: are we there yet? Curr Med Chem. 2014;21(5):553–74. https://doi.org/10.2174/09298673113206660325.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, et al. Systemic treatments in MDM2 positive intimal sarcoma: a multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2019. https://doi.org/10.1002/cncr.32508.

    Article  PubMed  Google Scholar 

  21. Zhang Q, Zeng SX, Lu H. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem. 2014;85:281–319. https://doi.org/10.1007/978-94-017-9211-0_16.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Yang L, Song T, Cheng Q, Chen L, Chen J. Mutant p53 sequestration of the MDM2 acidic domain inhibits E3 ligase activity. Mol Cell Biol. 2019. https://doi.org/10.1128/mcb.00375-18.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Dyson NJ. RB1: a prototype tumor suppressor and an enigma. Genes Dev. 2016;30(13):1492–502. https://doi.org/10.1101/gad.282145.116.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. D’Arcangelo D, Tinaburri L, Dellambra E. The role of p16(INK4a) pathway in human epidermal stem cell self-renewal, aging and cancer. Int J Mol Sci. 2017. https://doi.org/10.3390/ijms18071591.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Fu HC, Chuang IC, Yang YC, Chuang PC, Lin H, Ou YC, et al. Low P16(INK4A) expression associated with high expression of cancer stem cell markers predicts poor prognosis in cervical cancer after radiotherapy. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19092541.

    Article  PubMed  PubMed Central  Google Scholar 

  26. He SH, Sharpless NE. Senescence in health and disease. Cell. 2017;169(6):1000–11. https://doi.org/10.1016/j.cell.2017.05.015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Noe M, Hackeng WM, de Leng WWJ, Vergeer M, Vleggaar FP, Morsink FHM, et al. Well-differentiated pancreatic neuroendocrine tumor in a patient with familial atypical multiple mole melanoma syndrome (FAMMM). Am J Surg Pathol. 2019. https://doi.org/10.1097/PAS.0000000000001314.

    Article  PubMed  Google Scholar 

  28. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47–53. https://doi.org/10.1038/nature14664.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Meder L, Konig K, Ozretic L, Schultheis AM, Ueckeroth F, Ade CP, et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int J Cancer. 2016;138(4):927–38. https://doi.org/10.1002/ijc.29835.

    Article  CAS  PubMed  Google Scholar 

  30. Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Inagaki A, Schultz N, et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov. 2014;4(9):1014–21. https://doi.org/10.1158/2159-8290.CD-14-0380.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Rickman DS, Beltran H, Demichelis F, Rubin MA. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat Med. 2017;23(6):1–10. https://doi.org/10.1038/nm.4341.

    Article  CAS  PubMed  Google Scholar 

  32. Cheng L, Jones TD, McCarthy RP, Eble JN, Wang MS, MacLennan GT, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol. 2005;166(5):1533–9. https://doi.org/10.1016/S0002-9440(10)62369-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Pan CX, Zhang H, Lara PN Jr, Cheng L. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev Anticancer Ther. 2006;6(12):1707–13. https://doi.org/10.1586/14737140.6.12.1707.

    Article  CAS  PubMed  Google Scholar 

  34. Abat D, Demirhan O, Inandiklioglu N, Tunc E, Erdogan S, Tastemir D, et al. Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer. Oncol Lett. 2014;8(1):25–32. https://doi.org/10.3892/ol.2014.2108.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Worst TS, Weis CA, Stohr R, Bertz S, Eckstein M, Otto W, et al. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Sci Rep. 2018. https://doi.org/10.1038/s41598-018-32569-x.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Kouba EJ, Cheng L. Understanding the genetic landscape of small cell carcinoma of the urinary bladder and implications for diagnosis, prognosis, and treatment: a review. JAMA Oncol. 2017;3(11):1570–8. https://doi.org/10.1001/jamaoncol.2016.7013.

    Article  PubMed  Google Scholar 

  37. Gupta A, Shah K, Oza MJ, Behl T. Reactivation of p53 gene by MDM2 inhibitors: a novel therapy for cancer treatment. Biomed Pharmacother. 2019;109:484–92. https://doi.org/10.1016/j.biopha.2018.10.155.

    Article  CAS  PubMed  Google Scholar 

  38. Khurana A, Shafer DA. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). Oncotargets Ther. 2019;12:2903–10. https://doi.org/10.2147/Ott.S172315.

    Article  Google Scholar 

  39. Oliner JD, Saiki AY, Caenepeel S. The role of MDM2 amplification and overexpression in tumorigenesis. Cold Spring Harb Perspect Med. 2016. https://doi.org/10.1101/cshperspect.a026336.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Weisberg E, Halilovic E, Cooke VG, Nonami A, Ren T, Sanda T, et al. Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097. Mol Cancer Ther. 2015;14(10):2249–59. https://doi.org/10.1158/1535-7163.Mct-15-0429.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Giedl J, Rogler A, Wild A, Riener MO, Filbeck T, Burger M, et al. TERT core promotor mutations in early-onset bladder cancer. J Cancer. 2016;7(8):915–20. https://doi.org/10.7150/jca.15006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Avogbe PH, Manel A, Vian E, Durand G, Forey N, Voegele C, et al. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. EBioMedicine. 2019;44:431–8. https://doi.org/10.1016/j.ebiom.2019.05.004.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Zheng XY, Jian ZG, Bezerra SM, Faraj SF, Munari E, Fallon JT, et al. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol. 2014. https://doi.org/10.1186/s13045-014-0047-7.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Rane JK, Simms MS, Maitland NJ. Re: Yves Allorya, Willemien Beukers, Ana Sagrera, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014;65:360-6: telomerase expression and stem cells: urologic epithelial perspective. Eur Urol. 2014;65(6):E85–6. https://doi.org/10.1016/j.eururo.2014.02.030.

    Article  CAS  PubMed  Google Scholar 

  45. Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Can Res. 2013;73(24):7162–7. https://doi.org/10.1158/0008-5472.Can-13-2498.

    Article  CAS  Google Scholar 

  46. Fujii T, Shimada K, Tatsumi Y, Hatakeyama K, Obayashi C, Fujimoto K, et al. microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1. BMC Cancer. 2015;15:818. https://doi.org/10.1186/s12885-015-1846-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Van Batavia J, Yamany T, Molotkov A, Dan H, Mansukhani M, Batourina E, et al. Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol. 2014;16(10):982–91. https://doi.org/10.1038/ncb3038.

    Article  CAS  PubMed  Google Scholar 

  48. Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer: what limits limited disease? Lung Cancer. 2002;37(3):271–6.

    Article  Google Scholar 

  49. Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(3):300–11. https://doi.org/10.1016/j.jtho.2015.10.008.

    Article  PubMed  Google Scholar 

  50. Bryant CM, Dang LH, Stechmiller BK, Gilbert SM, Morris CG, Zlotecki RA. Treatment of small cell carcinoma of the bladder with chemotherapy and radiation after transurethral resection of a bladder tumor. Am J Clin Oncol. 2016;39(1):69–75. https://doi.org/10.1097/COC.0000000000000027.

    Article  CAS  PubMed  Google Scholar 

  51. Montie JE. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 64 patients. J Urol. 2005;173(6):1920–1. https://doi.org/10.1097/01.ju.0000161245.95285.b2.

    Article  PubMed  Google Scholar 

  52. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M.D. Anderson cancer experience. J Urol. 2004;172(2):481–4.

    Article  Google Scholar 

  53. Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol. 2005;174(1):93–6. https://doi.org/10.1097/01.ju.0000162085.20043.1f.

    Article  PubMed  Google Scholar 

  54. Walther PJ. Adjuvant/neo-adjuvant etoposide/cisplatin and cystectomy for management of invasive small cell carcinoma of the bladder. J Urol. 2002;167(4):285.

    Google Scholar 

  55. Pasquier D, Barney B, Sundar S, Poortmans P, Villa S, Nasrallah H, et al. Small cell carcinoma of the urinary bladder: a retrospective, multicenter rare cancer network study of 107 patients. Int J Radiat Oncol Biol Phys. 2015;92(4):904–10. https://doi.org/10.1016/j.ijrobp.2015.03.019.

    Article  PubMed  Google Scholar 

  56. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009;27(16):2592–7. https://doi.org/10.1200/Jco.2008.19.0256.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013;64(2):307–13. https://doi.org/10.1016/j.eururo.2012.04.020.

    Article  PubMed  Google Scholar 

  58. Bhatt VR, Loberiza FR Jr, Tandra P, Krishnamurthy J, Shrestha R, Wang J. Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder. Rare Tumors. 2014;6(1):5043. https://doi.org/10.4081/rt.2014.5043.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Kaushik D, Frank I, Boorjian SA, Cheville JC, Eisenberg MS, Thapa P, et al. Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. Int J Urol. 2015;22(6):549–54. https://doi.org/10.1111/iju.12729.

    Article  PubMed  Google Scholar 

  60. Lohrisch C, Murray N, Pickles T, Sullivan L. Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer. 1999;86(11):2346–52.

    Article  CAS  Google Scholar 

  61. Meijer RP, Meinhardt W, van der Poel HG, van Rhijn BW, Kerst JM, Pos FJ, et al. Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder. Int J Urol. 2013;20(8):778–84. https://doi.org/10.1111/iju.12038.

    Article  PubMed  Google Scholar 

  62. Bex A, Nieuwenhuijzen JA, Kerst M, Pos F, van Boven H, Meinhardt W, et al. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology. 2005;65(2):295–9. https://doi.org/10.1016/j.urology.2004.09.049.

    Article  PubMed  Google Scholar 

  63. Bex A, de Vries R, Pos F, Kerst M, Horenblas S. Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder. World J Urol. 2009;27(1):101–6. https://doi.org/10.1007/s00345-008-0304-x.

    Article  PubMed  Google Scholar 

  64. Mattes MD, Kan CC, Dalbagni G, Zelefsky MJ, Kollmeier MA. External beam radiation therapy for small cell carcinoma of the urinary bladder. Pract Radiat Oncol. 2015;5(1):e17–22. https://doi.org/10.1016/j.prro.2014.03.013.

    Article  PubMed  Google Scholar 

  65. Akamatsu H, Nakamura K, Ebara T, Inaba K, Itasaka S, Jingu K, et al. Organ-preserving approach via radiotherapy for small cell carcinoma of the bladder: an analysis based on the Japanese Radiation Oncology Study Group (JROSG) survey. J Radiat Res. 2019. https://doi.org/10.1093/jrr/rrz018.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Germino E, Fischer-Valuck BW, Rudra S, Rao YJ, Contreras J, Abraham C, et al. Radiation therapy as definitive local treatment in patients with limited-stage small cell carcinoma of the bladder: does total dose matter? Bladder Cancer. 2018;4(3):311–7. https://doi.org/10.3233/BLC-180165.

    Article  PubMed  PubMed Central  Google Scholar 

  67. van de Kamp M, Meijer R, Pos F, Kerst M, van Werkhoven E, van Rhijn B, et al. Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: characteristics, treatment, and outcome. Urol Oncol. 2018;36(6):307.e1–8. https://doi.org/10.1016/j.urolonc.2018.02.015.

    Article  Google Scholar 

  68. Hsu FS, Su CH, Huang KH. A comprehensive review of US FDA-approved immune checkpoint inhibitors in urothelial carcinoma. J Immunol Res. 2017;2017:6940546. https://doi.org/10.1155/2017/6940546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Schultheis AM, Scheel AH, Ozretic L, George J, Thomas RK, Hagemann T, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer. 2015;51(3):421–6. https://doi.org/10.1016/j.ejca.2014.12.006.

    Article  CAS  PubMed  Google Scholar 

  70. Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, et al. Transcriptomic and protein analysis of small-cell bladder cancer (SCBC) identifies prognostic biomarkers and DLL3 as a relevant therapeutic target. Clin Cancer Res. 2019;25(1):210–21. https://doi.org/10.1158/1078-0432.Ccr-18-1278.

    Article  PubMed  Google Scholar 

  71. Mandelkow T, Blessin NC, Lueerss E, Pott L, Simon R, Li WC, et al. Immune exclusion is frequent in small-cell carcinoma of the bladder. Dis Markers. 2019. https://doi.org/10.1155/2019/2532518.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–30. https://doi.org/10.1038/nature21349.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The National Natural Science Foundation of China (No. 81573003) and Zhejiang Province Natural Science Foundation and Zhejiang Society of Mathematical Medicine Joint Foundation (No. LSY19H160005).

Author information

Author notes

  1. Yanling Wang and Qijun Li have contributed equally to this work.

Authors and Affiliations

  1. Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, Zhejiang, China

    Yanling Wang, Qijun Li, Jing Wang, Yanan Xue, Hongming Pan & Da Li

  2. Second Department of Medical Oncology, The Fourth Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, Xinjiang, China

    Mengting Tong

  3. Deparment of ICU, Xiasha Campus, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310019, Zhejiang, China

    Haibo Xing

  4. Department of Medical Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310020, Zhejiang, China

    Changxing Huang

Authors
  1. Yanling Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qijun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mengting Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haibo Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yanan Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hongming Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Changxing Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Da Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Da Li.

Ethics declarations

Conflict of interests

The authors have declared that no competing interest exists.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Y., Li, Q., Wang, J. et al. Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up. Med Oncol 36, 98 (2019). https://doi.org/10.1007/s12032-019-1321-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-019-1321-x

Keywords

Search

Navigation